MedTrace Logo

Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome

NCT00584246 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-11-16

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of Pregabalin (Lyrica) in treating patients with Restless Legs Syndrome (RLS) in a double-blind, placebo-controlled trial.

Conditions

  • Restless Legs Syndrome

Interventions

DRUG

Pregabalin (Lyrica)

50 - 150 mg po qhs for 2 months

DRUG

Placebo

50 - 150 mg po qhs for 2 months

Sponsors & Collaborators

  • University of South Florida

    lead OTHER

Principal Investigators

  • Theresa A Zesiewicz, MD · University of South Florida

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584246 on ClinicalTrials.gov